Prevalence of Neuropsychiatric Symptoms Up for Autoimmune Rheumatic Disease
TUESDAY, Aug. 1, 2023 (HealthDay News) -- The prevalence of all self-reported neuropsychiatric symptoms is significantly higher in those with systemic autoimmune rheumatic diseases (SARDs) versus controls, according to a study published online July 27 in Rheumatology.
Melanie Sloan, Ph.D., from the University of Cambridge in the United Kingdom, and colleagues examined a wider range of potential neuropsychiatric symptoms in SARDs than have been reported previously using data from 1,853 SARD patients, 463 controls, and 289 clinicians as part of the INSPIRE research project. A total of 113 in-depth interviews were analyzed thematically. The means of survey items were compared between patients and controls, eight different SARD groups, and clinician specialties.
The researchers found that compared with controls, SARDs had higher self-reported prevalence rates of all 30 neuropsychiatric symptoms investigated, including cognitive, sensorimotor, and psychiatric. Of SARD patients, validated instruments revealed that 55 and 57 percent currently had depression or anxiety, respectively. Limits to knowledge, guidelines, objective tests, and interspecialty cooperation; subjectivity, invisibility, and believability of symptoms; and under-eliciting, under-reporting, and under-documenting were barriers to identifying neuropsychiatric symptoms. The proportion of clinicians who reported never/rarely asking patients about mental health symptoms was much lower than the percentage of patients who reported never/rarely being asked in clinic (4 versus 74 percent). More than 50 percent of SARD patients had never/rarely reported their mental health symptoms to clinicians, which was underestimated by clinicians at less than 10 percent.
"The low level of reporting we identified is a major concern as problems with mental health, fatigue, and cognition can be life-changing, and sometimes life-threatening," Sloan said in a statement.
Several authors disclosed ties to the pharmaceutical industry.
Related Posts
AHA News: Protegiendo a las personas LGBTQ de los riesgos del aislamiento social para la salud
VIERNES, 21 de octubre de 2022 (American Heart Association News) -- Las formas...
El delirio postoperatorio podría ser señal de un deterioro mental más rápido
MARTES, 21 de marzo de 2023 (HealthDay News) -- Los adultos mayores con...
Psilocybin May Help Some Who Battle Anorexia
TUESDAY, Aug. 1, 2023 (HealthDay News) -- One dose of the hallucinogenic...
Stakes Are High Ahead of FDA Panel Vote on ALS Drug
MONDAY, March 28, 2022 (HealthDay News) -- Advocacy groups are pressing U.S....